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In this issue ofCell Stem Cell, Westerterp et al. demonstrate that cholesterol flux through splenic phagocytes
regulates hematopoietic stem and multipotential progenitor cell mobilization from the bone marrow. These
exciting findings suggest new avenues for therapy of myeloproliferative disorders and atherosclerosis.Although cholesterol trafficking was origi-
nally considered in the narrow light of
nutrient supply to and toxic lipid removal
from peripheral cells, it is now recognized
to communicate with and indeed to regu-
late specialized cell functions in a wide
variety of systems, including immune,
neurologic, respiratory, and endocrine.
Since dyslipidemia is commonly associ-
ated with increased circulating neutro-
phils and monocytes in humans and this
combined disorder is pivotal to athero-
sclerosis, there has been increased in-
terest in defining the molecular connec-
tions between cholesterol homeostasis
and blood cell homeostasis.
ATP Binding Cassette (ABC) A1 is
a ‘‘transporter’’ that regulates homeo-
static efflux of cholesterol from cells to
the acceptor lipid-free apolipoprotein A-I
(apoA-I), and ABCG1 is a regulator of
cholesterol efflux to high-density lipo-
protein (HDL). Together, these proteins
collaborate asmaster gatekeepers of cho-
lesterol mobilization from macrophages
and other cells, including hematopoietic
stem and multipotential progenitor cells
(HSPCs). Remarkably, mice dually defi-
cient in ABCA1 and ABCG1 develop a
myeloproliferative disorder characterized
by dramatic neutrophilia and monocyto-
sis as well as infiltration of several organs
with neutrophils and cholesterol-laden
macrophage foam cells (Yvan-Charvet
et al., 2010a). Groundbreaking work from
Tall and colleagues has demonstrated
that Abca1/Abcg1/ mice display ab-
normal, cell-autonomous proliferation of
LinSca-1+Kit+ (LSK) HSPCs, granulo-
cyte-monocyte progenitors (GMPs), and
common myeloid progenitors (CMPs) in
the marrow (Yvan-Charvet et al., 2010a).
This defect derives from augmented LSKcell responsiveness to interleukin (IL)-3
and granulocyte macrophage-colony
stimulating factor (GM-CSF) due to
increased cell-surface display of the
common b subunit of the IL-3/GM-CSF
receptor in expanded lipid raft mem-
brane microdomains. Interestingly, HSPC
growth factor responsiveness parallels
membrane cholesterol loading. HSPC
proliferation, monocytosis, and neutro-
philia in Abca1/Abcg1/ mice are all
reversed by mobilizing cholesterol with
HDL infusion or expression of an apoA-I
transgene (Murphy et al., 2011; Yvan-
Charvet et al., 2010a).
In this issue of Cell Stem Cell, Wester-
terp et al. advance our understanding of
myelopoiesis regulation by cholesterol
efflux by showing that ABCA1/ABCG1
also control HSPCmobilization and extra-
medullary hematopoiesis. Furthermore,
they link this regulation to a complex inter-
play between splenic phagocytes and
marrow HSPCs through an IL-23/IL-17/
granulocyte-CSF (G-CSF)/stromal cell-
derived factor (SDF)-1 pathway (Wester-
terp et al., 2012). The investigators
demonstrate that Abca1/Abcg1/
mice have increased LSK, GMP, and
CMP cells, as well as increased colony
forming units of multipotential progenitors
(CFU-GEMM) and GMPs (CFU-GM) in
blood, spleen, and marrow, indicating
HSPC mobilization and extramedullary
hematopoiesis. Bone marrow transfer
studies indicated that this phenotype
was not HSPC intrinsic, but rather was
due to increased plasma levels of G-CSF.
Past work from Ley and colleagues had
identified a neutrophil rheostat wherein
tissue phagocyte-derived IL-23 induces
T cell production of IL-17, which in turn
induces G-CSF and granulopoiesis in theCell Stem Cell 1bone marrow (Stark et al., 2005). In the
present work, Westerterp et al. implicate
this axis, showing that upregulated IL-23
inAbca1/Abcg1/ splenic phagocytes
(macrophages and dendritic cells) drives
HSPC mobilization through consequent
IL-17 and G-CSF induction. G-CSF is
shown to reduce bone marrow levels of
the HSPC maintenance and tethering
factor SDF-1 through decreasing its
expression via bone marrow osteoblasts.
G-CSF also depletes the number of
HSPC-supportive marrow osteoblasts
via skewingGMP fate away from the oste-
oblast-supportive macrophage lineage
and toward that of neutrophils. Finally,
the authors show that either HDL
infusion or apoA-I overexpression not
only rescues HSPC mobilization, splenic
IL-23, and plasma G-CSF in Abca1/
Abcg1/mice, but also in mice with an
oncogenic Flt3-ITD mutation that confers
a myeloproliferative disorder. Taken
together, cholesterol flux through extra-
medullary phagocytes regulates HSPC
mobilization and granulopoiesis through
remotely modifying the marrow osteo-
blastic niche.
This seminal work raises a number
of interesting questions. One wonders
whether the remarkable basal induction
of IL-23 in Abca1/Abcg1/ macro-
phages that drives HSPC mobilization is
cell intrinsic (e.g., driven by sterol over-
load) or cell-extrinsic (e.g., dependent on
a serum factor or ‘‘damage-associated
molecular pattern’’ that may also be
sequestered by HDL). As Abca1/
Abcg1/ macrophages are more sus-
ceptible to apoptosis (Yvan-Charvet
et al., 2010b), it is possible that apoptosis
may serve as a brake upon IL-23
production in splenic phagocytes. As1, August 3, 2012 ª2012 Elsevier Inc. 143
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Previewsa high-cholesterol diet has also been
reported to increase circulating progen-
itor cells through a mechanism involving
increased plasma SDF-1 (Gomes et al.,
2010), one wonders whether ABC trans-
porter deletion invokes a similar mecha-
nism. Liver X Receptor (LXR), an oxy-
sterol-sensitive nuclear receptor, serves
as a central driver of cholesterol efflux
through induction of ABCA1 and ABCG1
expression. Interestingly, LXR-deficient
mice are reported to have increased cir-
culating neutrophils, but, unlike Abca1/
Abcg1/ mice, neutrophilia is caused by
impaired neutrophil clearance. Moreover,
LXR-deficient mice also lack evidence for
increased medullary or extramedullary
hematopoiesis and have normal plasma
IL-17 and G-CSF levels (Hong et al.,
2012). This suggests that cholesterol flux
may regulate myeloid homeostasis at
several independent levels. Conversely,
given that microRNA-33 suppresses
cholesterol efflux through coordinate
silencing of ABCA1 and ABCG1 and
reduction of HDL biogenesis (Rayner
et al., 2010), one wonders whether it will
be found to be a master regulator of
HSPC proliferation and mobilization. Ex-
panding to the organ level, because the
in vivo pathway for cholesterol disposal
from tissue macrophages into the feces
(‘‘reverse cholesterol transport’’ [RCT])
also involves critical checkpoints in the
liver (e.g., HDL uptake by scavenger
receptor-BI), perhaps hepatic/cholestatic
disorders will be found to modify HSPC
mobilization. It will be interesting to
next address questions related to other
disease situations. For example, address-
ing how the cholesterol-reducing statins
or disorders such as diabetes mellitus, in
which ABCG1 is downregulated (Mauldin
et al., 2008), affect HSPC mobilization144 Cell Stem Cell 11, August 3, 2012 ª2012will be of great interest. Finally, Wester-
terp’s work clearly also opens up the
possibility that HDL quantity/function
may be an important disease modifier in
human myeloproliferative disorders.
The evolutionary connection between
RCT and HSPC proliferation/mobilization
may seem unclear at first pass. However,
good evidence suggests that HDL and
RCT represent an ancient arm of the
innate immune system that serves to
sequester and clear microbial lipids
(Azzam and Fessler, 2012). Moreover,
cholesterol efflux is integral to homeo-
static clearance of apoptotic neutrophils
by phagocytes. Apoptotic cells are a
substantial cholesterol bolus for
phagocytes; importantly, LXR activation
in phagocytes promotes uptake of
apoptotic cells, and ABC transporters
preserve phagocyte viability by clearing
excess sterol (Yvan-Charvet et al.,
2010b). Taken in the light of these
observations, it may be less surprising
that RCT can regulate emergency mobili-
zation of HSPCs. In times of famine,
low macrophage and HSPC cholesterol
levels may have favored the economy of
reduced HSPC proliferation and mobiliza-
tion. In times of surfeit, as developed
nations now experience, macrophage/
HSPC cholesterol overload may lead to
maladaptive responses. It is however
interesting to speculate that HSPC prolif-
eration may perhaps at least temporarily
serve to dilute/consume excess cellular
sterols.
Evolutionary speculations aside, in an
era of rapidly expanding therapeutic strat-
egies for augmenting RCT in the battle
against atherosclerotic cardiovascular
disease, work such as that by Westerterp
and colleagues may very possibly open
up new, valuable avenues for the thera-Elsevier Inc.peutic manipulation of HSPC mobiliza-
tion, and for the treatment of hemato-
logical malignancies. Furthermore, it
provides broader insight into the rising
flood of disease accompanying obesity
and metabolic syndrome in our popula-
tion. The purview of the simple sterol
backbone continues to expand with no
clear end in sight.REFERENCES
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